Cargando…

Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial

BACKGROUND: Vascular endothelial growth factor (VEGF)-targeted therapy is effective in patients with ovarian cancer. Whether adipose tissue (AT) could predict the efficacy of VEGF receptor (VEGFR) inhibitors in ovarian cancer is unknown. We aimed to evaluate the ability of distinct AT depots to pred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Xin, Xie, Chuanbo, Tang, Jie, He, Wenzhuo, Yang, Fan, Tian, Wenfang, Li, Jundong, Yang, Qiuxia, Shen, Jingxian, Xia, Liangping, Lan, Chunyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534164/ https://www.ncbi.nlm.nih.gov/pubmed/33012286 http://dx.doi.org/10.1186/s12916-020-01733-4

Ejemplares similares

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
por: Pan, Zhongmian, et al.
Publicado: (2023)

Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial
por: Hou, Zhiguo, et al.
Publicado: (2023)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2020)

Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
por: Wu, Yawen, et al.
Publicado: (2022)

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
por: Chen, Wei, et al.
Publicado: (2020)

Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2021)

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
por: Zhang, Jindi, et al.
Publicado: (2019)

Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases
por: Cheng, Yuan, et al.
Publicado: (2018)

Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study
por: Huang, Qi, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Lan, Chunyan, et al.
Publicado: (2020)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2023)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
por: Ni, Jing, et al.
Publicado: (2020)

Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer
por: Ikeda, Asami, et al.
Publicado: (2020)

A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score
por: Yang, Fan, et al.
Publicado: (2023)

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2020)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma
por: Chen, Wei, et al.
Publicado: (2022)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2020)

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
por: Qiu, Hu, et al.
Publicado: (2022)

Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report
por: Zhang, Mingzi, et al.
Publicado: (2017)

Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report
por: Sun, Huiting, et al.
Publicado: (2018)

Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
por: Wang, Zhongyu, et al.
Publicado: (2021)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
por: Deng, Linghui, et al.
Publicado: (2017)

Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report
por: Liu, Qiuxia, et al.
Publicado: (2019)

Annexin A3 Is a Potential Predictor of Platinum Resistance in Epithelial Ovarian Cancer Patients in a Prospective Cohort
por: Jin, Ying, et al.
Publicado: (2015)

Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

Predictive value of prognostic nutritional and systemic immune-inflammation indices for patients with microsatellite instability-high metastatic colorectal cancer receiving immunotherapy
por: Yi, Jiahong, et al.
Publicado: (2023)

Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer
por: Yang, Lin, et al.
Publicado: (2023)

Bioinformatic profiling identifies a platinum‐resistant–related risk signature for ovarian cancer
por: Wu, Ce, et al.
Publicado: (2019)

Synthesis of ultrathin platinum nanoplates for enhanced oxygen reduction activity
por: Liu, Hongpo, et al.
Publicado: (2017)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study
por: Zhao, Shen, et al.
Publicado: (2020)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b3givjgq9v5dcm77buq43rnd0e